These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12608943)

  • 61. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The BsmI vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intake on bone mineral density.
    Kiel DP; Myers RH; Cupples LA; Kong XF; Zhu XH; Ordovas J; Schaefer EJ; Felson DT; Rush D; Wilson PW; Eisman JA; Holick MF
    J Bone Miner Res; 1997 Jul; 12(7):1049-57. PubMed ID: 9200004
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease.
    Di Somma C; Colao A; Pivonello R; Klain M; Faggiano A; Tripodi FS; Merola B; Salvatore M; Lombardi G
    Clin Endocrinol (Oxf); 1998 May; 48(5):655-62. PubMed ID: 9666879
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Two polymorphisms in the vitamin D receptor gene--association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study.
    Tofteng CL; Jensen JE; Abrahamsen B; Odum L; Brot C
    J Bone Miner Res; 2002 Aug; 17(8):1535-44. PubMed ID: 12162507
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
    Pivonello R; Faggiano A; Di Somma C; Klain M; Filippella M; Salvatore M; Lombardi G; Colao A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2349-52. PubMed ID: 10404801
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Bone density and bone metabolism regulated by vitamin D receptor allele polymorphism in a German study sample].
    Baltzer AW; Reinecke J; Wehling P; Granrath M; Schulitz KP
    Z Orthop Ihre Grenzgeb; 1999; 137(3):273-9. PubMed ID: 10441835
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
    Cesareo R; Di Stasio E; Vescini F; Campagna G; Cianni R; Pasqualini V; Romitelli F; Grimaldi F; Manfrini S; Palermo A
    Osteoporos Int; 2015 Apr; 26(4):1295-302. PubMed ID: 25524023
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
    Park JH; Park KH; Cho S; Choi YS; Seo SK; Lee BS; Park HS
    Menopause; 2013 Jul; 20(7):747-53. PubMed ID: 23511701
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vitamin D receptor genotype BB is associated with higher serum osteocalcin in first pregnancy.
    Feuz J; Wisser J; Heufelder A; Joba W; Zimmermann R; von Mandach U
    J Perinat Med; 2009; 37(5):491-5. PubMed ID: 19492922
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of vitamin D receptor polymorphisms with osteoporosis in mexican postmenopausal women.
    Lisker R; López MA; Jasqui S; Ponce De León Rosales S; Correa-Rotter R; Sánchez S; Mutchinick OM
    Hum Biol; 2003 Jun; 75(3):399-403. PubMed ID: 14527203
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Vitamin D receptor gene polymorphism: correlation with bone mineral density in a Brazilian population with insulin-dependent diabetes mellitus.
    Hauache OM; Lazaretti-Castro M; Andreoni S; Gimeno SG; Brandão C; Ramalho AC; Kasamatsu TS; Kunii I; Hayashi LF; Dib SA; Vieira JG
    Osteoporos Int; 1998; 8(3):204-10. PubMed ID: 9797903
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density.
    Mencej-Bedrac S; Prezelj J; Kocjan T; Teskac K; Ostanek B; Smelcer M; Marc J
    J Mol Endocrinol; 2009 Mar; 42(3):239-47. PubMed ID: 19131500
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis].
    Wang C; He JW; Qin YJ; Zhang H; Hu WW; Liu YJ; Zhang ZL
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2958-62. PubMed ID: 20137703
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The bone mass density in postmenopausal women using hormonal replacement therapy in relation to polymorphism in vitamin D receptor and estrogen receptor genes.
    Brodowska A; Starczewski A; Brodowski J; Szydłowska I; Nawrocka-Rutkowska J
    Gynecol Endocrinol; 2009 May; 25(5):315-23. PubMed ID: 19903038
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 80. VDR polymorphisms effect on bone mineral density in Polish postmenopausal women.
    Spinek AE; Majsterek I; Walczak A; Rosset I; Sewerynek E; Żądzińska E
    Homo; 2021 Sep; 72(3):239-260. PubMed ID: 34296242
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.